CELDARA MEDICAL, LLC
CAR-engineered regulatory T cells (CAR Tregs) that recognize aggregated SOD1 and produce BDNF for ALS treatment
- Sector
- Biotech
- Headquarters
- Lebanon, NH
- Total capital
- $47.9M
- Federal grants
- $43.9M
- 59 awards · 2015–2026
- Rank in peer group#1 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $4M
- 6 awards · Health and Human S, Small Business Adm
- Rank in Biotech#97 of 4373
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Engineered Tregs as a therapy to Gaucher syndrome$311K
- Federal grantHealth and Human S · Phase II · Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma$1M
- Federal grantHealth and Human S · Phase II · Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$921K
- Federal grantHealth and Human S · Phase I · Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke$421K
- Federal grantHealth and Human S · Phase II · A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$956K
- Federal grantHealth and Human S · Phase II · Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma$1.2M
- Federal contractSmall Business Adm · Regional Innovation Clusters For The Small Business Administration (sba), The Office Of Investment And Innovation (oii)$480K
Show 57 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$921K
- Federal grantHealth and Human S · Phase II · Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$1.0M
- Federal grantHealth and Human S · Phase II · Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas$998K
- Federal grantHealth and Human S · Phase II · A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$994K
- Federal grantHealth and Human S · Phase I · Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)$467K
- Federal grantHealth and Human S · Phase I · Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke$232K
- Federal grantHealth and Human S · Phase II · Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$999K
- Federal grantHealth and Human S · Phase II · Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$769K
- Federal grantHealth and Human S · Phase II · Preclinical development of an important, broad-spectrum antibody for pandemic influenza$1.0M
- Federal grantHealth and Human S · Phase II · A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome$1M
- Federal grantHealth and Human S · Phase II · Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes$300K
- Federal grantHealth and Human S · Phase II · Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$713K
- Federal grantHealth and Human S · Phase I · Development of a broad spectrum antimicrobial to combat chronic lung infection$301K
- Federal grantHealth and Human S · Phase I · CAR T platform to treat solid tumors$368K
- Federal grantHealth and Human S · Phase II · Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas$300K
- Federal grantHealth and Human S · Phase II · Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$974K
- Federal grantHealth and Human S · Phase I · A Novel Broad-spectrum Antiviral Agent$291K
- Federal grantHealth and Human S · Phase II · Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas$274K
- Federal grantHealth and Human S · Phase II · Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM$747K
- Federal grantHealth and Human S · Phase II · Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$985K
- Federal grantHealth and Human S · Phase I · A Novel Broad-spectrum Antiviral Agent$300K
- Federal grantHealth and Human S · Phase I · Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)$299K
- Federal contractHealth and Human S · SBIR Topic 081: Adjuvant Development For Vaccines Against Infectious Or Immune-mediated Diseases$600K
- Federal grantHealth and Human S · Phase II · Cellular Immunotherapy for Systemic Sclerosis$731K
- Federal grantHealth and Human S · Phase II · Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM$1.7M
- Federal grantHealth and Human S · Phase I · Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics)$258K
- Federal grantHealth and Human S · Phase II · Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$2.9M
- Federal grantHealth and Human S · Phase I · A novel antibody therapy for Sin Nombre virus infection$294K
- Federal grantHealth and Human S · Phase II · Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma$738K
- Federal grantHealth and Human S · Phase I · Antimicrobial peptides to combat MDR ESKAPE pathogens$299K
- Federal grantHealth and Human S · Phase II · DRIVEN: Accelerating Medical Entrepreneurship in the Northeast$3.2M
- Federal grantHealth and Human S · Phase II · Cellular Immunotherapy for Systemic Sclerosis$750K
- Federal contractHealth and Human S · Discovery Of Parasite-derived Tolerogenic Adjuvants$599K
- Federal grantHealth and Human S · Phase II · Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM$224K
- Federal grantHealth and Human S · Phase II · Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$295K
- Federal grantHealth and Human S · Phase I · A novel antibody therapy for Sin Nombre virus infection$594K
- Federal grantHealth and Human S · Phase II · Complex 3-Dimensional in vitro Human Skin Tissue Models for Scleroderma$1.5M
- Federal grantHealth and Human S · Phase I · Specificity and safety of a targeted therapy against triple negative breast cancer$300K
- Federal contractHealth and Human S · Igf::ot::igf "discovery Of Novel Helminth Immunomodulatory Proteins For Autoimmune Diseases"$598K
- Federal grantHealth and Human S · Phase I · Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$446K
- Federal grantHealth and Human S · Phase II · Development of GIFT4: a B cell focused immunotherapy for cancer$1.0M
- Federal grantHealth and Human S · Phase I · Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$54K
- Federal grantHealth and Human S · Phase II · Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus$300K
- Federal grantHealth and Human S · Phase II · Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$750K
- Federal grantHealth and Human S · Phase I · Complex 3-Dimensional in Vitro Human Skin Tissue Models for Scleroderma$225K
- Federal grantHealth and Human S · Phase I · Cellular Immunotherapy for SSc$225K
- Federal grantHealth and Human S · Phase I · Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma$225K
- Federal grantHealth and Human S · Phase I · Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome$800K
- Federal grantHealth and Human S · Phase II · Development of GIFT4: a B cell focused immunotherapy for cancer$2M
- Federal grantHealth and Human S · Phase II · Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$750K
- Federal grantHealth and Human S · Phase II · Therapy of transplantation-induced oxidative injury using polymeric antioxidants$734K
- Federal contractHealth and Human S · Igf::ot::igf Multiplexed Biomarker Assay For Classification Of Patients With Systemic Sclerosis$1.5M
- Federal grantHealth and Human S · Phase II · Therapy of transplantation-induced oxidative injury using polymeric antioxidants$1.5M
- Federal grantHealth and Human S · Phase II · Gene Expression Signatures to Predict Treatment Response in Systemic Sclerosis$855K
- Federal grantHealth and Human S · Phase II · Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF$225K
- Federal grantHealth and Human S · Phase I · Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL$299K
- Federal contractHealth and Human S · R&d- Medical: Biomedical (basic Research) Igf::ot::igf$223K
Federal awards are summed by year (64 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#1 · top 1%
- Linked publications#86 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 3- PendingImproved Method And System For Cell TherapyUSPTOApplication PCTUS2023072432
- PendingMethod And System For Cell TherapyUSPTOApplication 63371939
- PendingCompositions And Methods For Dendritic Cell Modulation In Post-ischemic WoundsUSPTOApplication PCTUS2009005995
Recent research by its founders
- Pharmacological administration of anti-oxidative APP-103 protects the acute kidney injury by regulating the mitochondrial function and ferroptosis20250 cites
- Data from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma20230 cites
- Figure S1 from Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma20230 cites
Related companies, and why
- Tissue Genesis, IncSimilar federal contract value in Biotech · $4.2M in contracts
- ALAMAR BIOSCIENCES, INC.Similar federal contract value in Biotech · $4.1M in contracts
- CAIRN BIOSCIENCES INCSimilar federal contract value in Biotech · $4M in contracts
- BioQ Pharma IncSimilar federal contract value in Biotech · $4M in contracts
- ANTAGEN BIOSCIENCES INCSimilar federal contract value in Biotech · $3.7M in contracts
- Proniras CorpSimilar federal contract value in Biotech · $3.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .